Payment overview · 2025
General Payments
$17,679.72
41 reported records · 10 companies
Healthcare provider profile · identity verified
Hady T Lichaa, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MURFREESBORO, TN · NPI 1336267533
Verified facts
What the public records show
CMS Open Payments records show Hady T Lichaa, M.D. received $17,679.72 in general payments during 2025 across 41 reported records.
Surmodics, Inc. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $9,159.07 | 51.8% | 15 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,848.63 | 16.1% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $2,650.04 | 15.0% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,063.53 | 11.7% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $249.74 | 1.4% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $246.03 | 1.4% | 6 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $150.13 | 0.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $123.26 | 0.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $108.71 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.58 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $10,787.50 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,700.00 | 1 |
| Food and Beverage | $2,301.14 | 28 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000.00 | 1 |
| Travel and Lodging | $891.08 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $9,159.07 | 15 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $9,159.07 | 15 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $7,871.88 | 6 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $2,704.87 | 2 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $2,187.50 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $2,000.00 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $368.04 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $249.74 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $150.13 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $150.13 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $149.66 | 3 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $149.66 | 3 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $136.33 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $123.26 | 1 | 2025 |
Source payment records
|
|||||
| Pounce LP Thrombectomy Normalized: pounce lp thrombectomy |
Device | Surmodics, Inc. | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| Pounce XL Thrombectomy Normalized: pounce xl thrombectomy |
Device | Surmodics, Inc. | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $108.71 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $94.50 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $80.58 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $63.53 | 1 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $7.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 158 |
| Metoprolol Succinate | Metoprolol Succinate | 519 | 166 |
| Clopidogrel | Clopidogrel Bisulfate | 426 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 117 |
| Carvedilol | Carvedilol | 298 | 96 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 244 | 74 |
| Eliquis | Apixaban | 224 | 59 |
| Losartan Potassium | Losartan Potassium | 221 | 68 |
| Ranolazine Er | Ranolazine | 203 | 63 |
| Spironolactone | Spironolactone | 182 | 67 |
| Torsemide | Torsemide | 177 | 65 |
| Xarelto | Rivaroxaban | 174 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 54 |
| Lisinopril | Lisinopril | 141 | 48 |
| Ezetimibe | Ezetimibe | 110 | 37 |
| Chlorthalidone | Chlorthalidone | 104 | 31 |
| Cilostazol | Cilostazol | 100 | 31 |
| Repatha Sureclick | Evolocumab | 100 | 17 |
| Farxiga | Dapagliflozin Propanediol | 91 | 24 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 87 | 30 |
| Potassium Chloride | Potassium Chloride | 82 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 23 |
| Entresto | Sacubitril/Valsartan | 66 | 16 |
| Eplerenone | Eplerenone | 63 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 61 | 15 |
| Nitroglycerin | Nitroglycerin | 58 | 36 |
| Colchicine | Colchicine | 57 | 24 |
| Furosemide | Furosemide | 56 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Atenolol | Atenolol | 51 | 12 |
| Brilinta | Ticagrelor | 48 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 16 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 13 |
| Irbesartan | Irbesartan | 31 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Valsartan | Valsartan | 31 | 14 |
| Prasugrel Hcl | Prasugrel Hcl | 27 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | 11 |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Inpefa | Sotagliflozin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,679.72 · 41 records | Surmodics, Inc. | ABRE, ACCOLADE SR, AVVIGO Guidance System, CHOCOLATE PTA BALLOON CATHETER, Coronary Undivided, DIAMONDBACK PERIPHERAL, ENDOCROSS Device, ESPRIT, General - Stents, Indigo System, PROTEGE RX, Pounce LP Thrombectomy, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce XL Thrombectomy, Repatha, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, Torus Stent Graft System, WINREVAIR | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error